Latest Conference Articles

November 16th 2014, 10:51am

Society for Neuro-Oncology Annual Meeting

The vaccine rindopepimut appears to help PFS and OS in patients with epidermal growth factor receptor variant III mutation in glioblastoma-a patient group with traditionally poor outcomes.

November 15th 2014, 12:49pm

Society for Neuro-Oncology Annual Meeting

Martin J. van den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands, discusses the BELOB trial, which examined bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma.

November 15th 2014, 12:30pm

Society for Neuro-Oncology Annual Meeting

The next-generation ALK inhibitor ceritinib showed clinically significant antitumor activity in patients with ALK-rearranged NSCLC, including those with brain metastases.

November 15th 2014, 11:24am

Society for Neuro-Oncology Annual Meeting

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, president, Society for Neuro-Oncology, discusses the ReACT study, which examined the rindopepimut vaccine (CDX-110) plus bevacizumab in patients with relapsed glioblastoma.

November 15th 2014, 10:36am

Society for Neuro-Oncology Annual Meeting

The vaccine rindopepimut plus bevacizumab induced tumor regression in a subset of patients with recurrent glioblastoma.

November 14th 2014, 3:16pm

Society for Neuro-Oncology Annual Meeting

The combination of bevacizumab and lomustine showed superior efficacy compared with either agent alone in patients with recurrent glioblastoma, warranting further study.

November 14th 2014, 1:43pm

Society for Neuro-Oncology Annual Meeting

Roeland GW Verhaak, PhD, Assistant Professor, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, discusses a study that examined the comprehensive and integrative genomic characterization of diffuse lower grade gliomas.

November 14th 2014, 11:02am

Society for Neuro-Oncology Annual Meeting

The combination of radiation therapy with procarbazine, CCNU, and vincristine prolonged OS and PFS compared with radiation therapy alone in grade 2 glioma.

November 14th 2014, 10:13am

Society for Neuro-Oncology Annual Meeting

Steven A. Toms, MD, director, neurosurgery, Geisinger Health System, discusses how targeting MEK can be an effective treatment strategy for CNS metastasis.

November 10th 2014, 10:05am

PER® New York Lung Cancer Symposium

Roy S. Herbst, MD, PhD, led some of the first trials of gefitinib, the EGFR inhibitor that helped introduce targeted therapies of this important mutation into the treatment landscape of non–small cell lung cancer.

November 10th 2014, 9:48am

PER® New York Lung Cancer Symposium

How should oncologists respond when initial treatment of EGFR-mutant or ALK-positive lung cancer with a tyrosine kinase inhibitor (TKI) no longer prevents all disease progression?

November 10th 2014, 8:18am

PER® New York Lung Cancer Symposium

Although testing for EGFR mutations and ALK rearrangements in patients with NSCLC has become widespread, the time has come to translate into clinical practice next-generation sequencing assays that provide exponentially more information about tumor biology.

November 10th 2014, 7:05am

PER® New York Lung Cancer Symposium

Benjamin P. Levy, MD, director, Thoracic Medical Oncology, Mount Sinai Beth Israel, associate director, Cancer Clinical Trials Office, Mount Sinai Hospital, Mt. Sinai School of Medicine, discusses new data on immunotherapy for lung cancer.

November 10th 2014, 7:02am

PER® New York Lung Cancer Symposium

Maria E. Arcila, MD, acting director, Diagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, discusses the benefits of new molecular diagnostic platforms for the treatment of lung cancer.

November 8th 2014, 9:26am

PER® New York Lung Cancer Symposium

Thomas J. Lynch, MD, from the Yale Cancer Center, explains how resistance occurs when treating lung cancer patients with EGFR TKIs.

November 7th 2014, 3:05pm

PER® New York Lung Cancer Symposium

Lung cancer experts provided insights into recent developments in the treatment of the disease, covering topics ranging from resistance to targeted therapies to immunotherapy agents under study, during the 9th Annual New York Lung Cancer Symposium in New York City.

November 7th 2014, 11:56am

PER® Chemotherapy Foundation Symposium (CFS)

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the approval of ramucirumab plus paclitaxel for gastric cancer

November 7th 2014, 9:24am

PER® Chemotherapy Foundation Symposium (CFS)

Both HPV-positive and -negative head and neck cancers are "outstanding candidates for immunotherapeutic strategies," said Andrew G. Sikora, MD, PhD, Baylor College of Medicine, at the 2014 Chemotherapy Foundation Symposium.

November 6th 2014, 12:53pm

PER® Chemotherapy Foundation Symposium (CFS)

Translating current and emerging knowledge of the molecular drivers of ovarian cancer is yielding promising new insights into potential clinical targets, moving treatment away from historical paradigms in favor of more personalized therapeutic approaches.

November 6th 2014, 12:41pm

PER® Chemotherapy Foundation Symposium (CFS)

PARP inhibitors represent an important class of emerging therapies for the treatment of patients with ovarian cancer and possibly other malignancies, but many scientific questions about the underlying molecular mechanisms that these agents target must be answered before they can be fully employed in clinical practice.